Table 1.
Demographic characteristics of included studies
| First author | Year | Country | Period | Patients | Proved after RP | Age | PSA | GS (range) | Disease | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Range | Mean ± SD | Range | ||||||||
| Baco22 | 2015 | USA | January 2010/September 2013. | 111 | 40 | 64* | 45–75 | 8.9* | 2.5–44 | 6–9 | ECE |
| Boesen26 | 2015 | Denmark | September 2011/September 2013 | 87 | 31 | 66.5*† | 47–74 | 12.0*† | 4.6–45.0 | 6–10 | ECE |
| Dominguez24 | 2018 | Colombia | May 2011/December 2013 | 79 | 31 | 61.1±7.5 | 39–78 | 7.0±7.25* | 0.02–31 | 6–10 | ECE |
| Feng4 | 2015 | USA | January 2010/December 2012 | 112 | 26 | 62.8±7.5 | NR | 8.2±7.2 | NR | ≥6 | EPE |
| Giganti13 | 2016 | Italy | January 2012/December 2014 | 70 | 23 | 63.97 | 58.9–70.5 | 6.82 | 5–9.88 | ≥6 | EPE |
| Kido14 | 2016 | Japan | April 2012/June 2014 | 43 | 18 | 69 | 54–84 | 7.57 | 1.2–30 | 6–9 | EPE |
| Matsuoka29 | 2017 | Japan | August 2007/March 2015 | 210 | 56 | 67 | 50–81 | 7.0 | 2.9–30.0 | 5–10 | ECE |
| Woo28 | 2015 | Korea | January 2012/December 2012 | 117 | 50 | 68.0±6.8 | 48–83 | 12.24 | 0.84–81.20 | 6–10 | ECE |
| Woo25 | 2016 | Korea | January 2012/December 2012 | 185 | 51 | 66.7±7.0 | 45–79 | 10.2±13.6 | 0.5–123 | 6–9 | ECE |
| Schieda32 | 2015 | Canada | April 2012/June 2014 | 65 | 42 | 62.8±6.0 | NR | 9.0±8.6 | NR | 6–10 | EPE |
| Jäderling21 | 2017 | Sweden | June 2014/January 2015 | 94 | 39 | 65.1* | 51.0–76.5 | 5.9* | 1.8–49.0 | NR | EPE |
| Kongnyuy33 | 2016 | USA | May 2007/December 2015 | 379 | 87 | 61.0* | 47–75 | 8.8* | 0.2–53.5 | ≥6 | EPE |
| Bittencourt31 | 2015 | Netherlands | January 2010/May 2013 | 133 | 60 | 61 | 47–72 | 8.6* | 2.5–76.0 | 5–10 | EPE |
| Rosenkrantz23 | 2015 | USA | NR | 180 | 46 | 64±8 | NR | 9.0±11.4 | NR | 6–9 | EPE |
| Lim30 | 2016 | Canada | January 2012/June 2014 | 113 | 76 | 61.9±5.4 | NR | 10.7±10.6 | NR | 6–9 | EPE |
| Rud12 | 2018 | Norway | December 2009/June 2012 | 183 | 103 | 65* | 60–68 | 7.9* | 5.8–11.5 | 6–9 | EPE |
| Krishna2 | 2017 | Canada | November 2012/May 2015 | 149 | 92 | 62.3±6.3 | NR | 6.33±3.29 | NR | 6–9 | EPE |
| Lim10 | 2015 | Canada | May 2012/May 2015 | 73 | 38 | 62.8±5.7 | NR | 10.7±10.6 | NR | 6–9 | EPE |
Notes: *Median, †only for proved.
Abbreviations: ECE, extracapsular extension; EPE, extraprostatic extension; GS, Gleason score; PSA, prostate-specific antigen; RP, radical prostatectomy; NR, not reported.